FDA ADVISORY COMMITTEE UNANIMOUSLY CONFIRMS EFFICACY AND CLINICAL BENEFIT OF LEQEMBI FOR EARLY ALZHEIMER’S DISEASE
CHICAGO, June 9, 2023 /PRNewswire/ — Today, an Advisory Committee to the Food and Drug Administration (FDA) unanimously endorsed the efficacy and clinical benefit of lecanemab (Leqembi™, Eisai) as part of the traditional approval process for this treatment. “The Alzheimer’s Association welcomes and celebrates this action by the FDA Advisory Committee to support traditional approval … Read more